To the Editor: Dr Wenzel's Editorial1 regarding anti-influenza drugs could be interpreted as dismissing the "first-generation" agents amantadine and rimantadine in favor of the newer "second-generation" neuraminidase inhibitors oseltamivir and zanamivir. Following a brief mention of the approved indications for the older agents, he provides a detailed list of the limitations of amantadine and rimantadine. The implication seems to be that the older agents are flawed and obsolete.
Johnson JR. Antiviral Agents for Influenza. JAMA. 2000;283(23):3069-3070. doi:10.1001/jama.283.23.3068c